The Noxopharm (ASX: NOX) share price gained a 21% boost today after the company announced groundbreaking research results.
The post Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone appeared first on The Motley Fool Australia. –
The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents.
Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to support cancer patients undertaking chemotherapy or radiotherapy treatment.
Noxopharm share price rockets upon survival benefit results
The company announced today that it would present its latest research findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium later this week.
The research pertains to extending the lives of patients who have late-stage prostate cancer.
Noxopharm’s LuPIN study enrolled a total of 56 patients with metastatic castration-resistant prostate cancer. Patients were treated with a combination of Veyonda with 177Lu-PSMA-617, an experimental radiopharmaceutical.
The goal of the combined (LuPIN) treatment was to slow or block tumour progression so that patients can live a better quality of life, and their survival is extended in a well-tolerated way.
The median overall survival (mOS) for the 56 participants in the LuPIN study was 19.7 months, an increase on the 17.1 months reported 12 months ago.
This survival benefit exceeds that reported for any current standard of care treatment, including one acquired by Pfizer Inc (NYSE: PFE) in 2016 for US$14 billion.
The LuPIN data reinforces Noxpharma’s belief that a combination of Veyonda and 177lutetium-PSMA-617 represents a “long-awaited forward leap” in cancer treatment.
Words from the CEO
Commenting on the company’s latest progress, CEO Dr Graham Kelly said:
Today’s clinical data continues to cement the view that Veyonda is on track to become a major new immunotherapy oncology drug of medical and commercial significance.
The DARRT program has already suggested this and the LuPIN program now confirms it. All of which augurs well for our upcoming IONIC program. Collectively, these three programs highlight the diversity of use and potential value of Veyonda.
The Noxopharm share price has gained more than 41% year-to-date and is up more than 250% over the past 12 months.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.